Genetic Testing Market Size & Growth Forecast 2027–2036, By Segments (Products & Services, Techniques, Test Type, End-use, Application), Regional Demand Trends (North America, Asia Pacific, Europe), Key Country Insights (U.S., Japan, South Korea, Germany, France, Italy), and Competitive Landscape
Market Size and Growth Outlook
Genetic Testing Market size was over USD 25.07 Billion in 2026 and is likely to grow at 12.79% CAGR between 2027 and 2036, attaining USD 83.53 Billion by 2036. The industry revenue for 2027 is calculated at USD 27.85 Billion.
Get more details on this report
Request Free Sample ReportGenetic Testing Market Intelligence Snapshot
Regional Market Dynamics
- North America held a 49.08% share in 2026, supported by advanced healthcare infrastructure, molecular diagnostics, precision medicine investment, and established research capabilities.
- Asia Pacific is the fastest-growing region, driven by rising healthcare expenditure, improving diagnostic infrastructure, research activity, and growing demand for precise disease detection.
Segment Momentum
- Kits & reagents accounted for 62.5% of the market in 2026, driven by their routine use across laboratories and clinical testing facilities for disease detection, inherited disorder screening, and precision medicine workflows.
- Carrier testing is expected to grow the fastest as awareness of inherited disease risks increases, encouraging greater use of genetic counseling, reproductive planning, and more accessible genetic testing services.
Market Expansion Drivers
- Increasing adoption of personalized medicine driving genetic diagnostics demand
- Expanding oncology and rare disease applications accelerating clinical genetic testing usage
- Growing direct-to-consumer genetic testing expanding consumer-driven genomics adoption
Leading Market Participants
- Major players in the genetic testing market include Illumina, Inc. (United States), Thermo Fisher Scientific Inc. (United States), QIAGEN N.V. (Netherlands), Quest Diagnostics Incorporated (United States), Natera, Inc. (United States), Myriad Genetics, Inc. (United States), BGI Genomics Co., Ltd. (China), 23andMe Holding Co. (United States), Siemens Healthineers AG (Germany), Abbott Laboratories (United States)
Global Market Forecast Snapshot
Market Outlook
- 2026 Market Size: USD 25.07 Billion
- 2027 Estimated Market Size: USD 27.85 Billion
- Projected Market Size: USD 83.53 Billion by 2036
- Growth Forecast: 12.79% CAGR (2027-2036)
Regional and Segment Outlook
- Leading Regional Market: North America
- High-Growth Regional Hub: Asia Pacific
- Core Revenue Segment: Kits & Reagents (Products & Services) | DNA Sequencing (Techniques) | Prenatal and Newborn Testing (Test Type) | Hospitals & Clinics (End-use) | Cancer Treatment (Application)
- Emerging Opportunity Segment: Software & Services (Products & Services) | DNA Sequencing (Techniques) | Carrier Testing (Test Type) | Diagnostic Laboratories (End-use) | Cancer Treatment (Application)
Market Growth Drivers and Industry Trends
Increasing adoption of personalized medicine driving genetic diagnostics demand
Healthcare providers are increasingly adopting personalized treatment approaches that rely on genetic insights to guide clinical decision-making, a trend that will propel the genetic testing market growth. Genetic diagnostics help identify inherited variations, predict disease susceptibility, and support the selection of therapies tailored to individual patient profiles. As precision medicine becomes more integrated into routine healthcare, demand continues to expand for genetic testing across preventive care, diagnosis, treatment planning, and long-term disease management.
Expanding oncology and rare disease applications accelerating clinical genetic testing usage
The expanding role of genetic analysis in oncology and rare disease diagnosis is creating broader clinical demand, making the genetic testing market a critical component of modern healthcare. Genetic testing enables clinicians to identify disease-associated mutations, confirm complex diagnoses, and support the development of targeted treatment strategies for patients with specific genetic characteristics. Improved understanding of genomic variations is also enhancing patient stratification and facilitating more informed therapeutic decisions across specialized medical settings.
Growing direct-to-consumer genetic testing expanding consumer-driven genomics adoption
Rising consumer interest in personal health information is encouraging wider adoption of direct-to-consumer genetic testing services, which will boost the genetic testing market demand. These services provide individuals with accessible insights into ancestry, inherited traits, wellness indicators, and selected genetic risk factors without requiring traditional clinical pathways. Greater awareness of preventive healthcare and advances in digital health platforms are supporting stronger consumer engagement with genomics while expanding participation beyond conventional healthcare environments.
| Growth Driver | Impact on CAGR | Regulatory Influence | Geographic Relevance | Adoption Rate | Impact Timeline |
|---|---|---|---|---|---|
| Increasing adoption of personalized medicine driving genetic diagnostics demand | 2.2% | High | North America, Europe | High | Near Term |
| Expanding oncology and rare disease applications accelerating clinical genetic testing usage | 2% | High | North America, Asia Pacific | High | Mid Term |
| Growing direct-to-consumer genetic testing expanding consumer-driven genomics adoption | 1.8% | Moderate | North America, Europe | High | Mid Term |
Unlock insights tailored to your business with our bespoke market research solutions.
Click to get your customized report now.
Regional Demand Dynamics
North America (Largest Region)
North America accounted for the largest share of the genetic testing market, representing 49.08% in 2026, supported by advanced healthcare infrastructure, broad availability of molecular diagnostic technologies, and growing integration of genetic information into clinical decision-making. Increasing awareness of inherited disorders and the role of genetic testing in disease risk assessment, diagnosis, and treatment selection is strengthening demand. The region also benefits from established research capabilities and continued investment in precision medicine, which are encouraging the adoption of increasingly sophisticated testing approaches across clinical and healthcare settings.
Asia Pacific (Fastest-Growing Region)
Asia Pacific is expected to register the fastest growth, driven by rising healthcare expenditure, improving diagnostic infrastructure, and increasing awareness of genetic diseases and personalized medicine. Expanding access to advanced molecular testing is enabling healthcare providers to incorporate genetic information into disease diagnosis and treatment planning. In addition, growing research activity, improving laboratory capabilities, and increasing demand for early and more precise disease detection are creating opportunities for genetic testing adoption across the region.
| Parameter | North America | Asia Pacific | Europe | Latin America | MEA |
|---|---|---|---|---|---|
| Innovation Hub i Scale Nascent Developing Advanced | |||||
| Cost-Sensitive Region i Scale Low Medium High | |||||
| Regulatory Environment i Scale Restrictive Neutral Supportive | |||||
| Demand Drivers i Scale Weak Moderate Strong | |||||
| Development Stage i Scale Emerging Developing Developed | |||||
| Adoption Rate i Scale Low Medium High | |||||
| New Entrants / Startups i Scale Sparse Moderate Dense | |||||
| Macro Indicators i Scale Weak Stable Strong |
Key Country Insights
United States 🇺🇸
Precision Diagnostics ExpansionThe U.S. genetic testing market is advancing through broader adoption of precision medicine, hereditary disease screening, and oncology diagnostics. Healthcare providers and testing companies continue improving genomic interpretation capabilities while expanding access through integrated clinical workflows and digital health platforms.
Germany 🇩🇪
Clinical Genomics IntegrationGermany is strengthening the genetic testing market by integrating genomic diagnostics into specialized healthcare and research networks. Laboratories emphasize high-quality testing standards, molecular diagnostics, and collaboration with healthcare providers to support personalized treatment planning and disease prevention initiatives.
Japan 🇯🇵
Preventive Genomic ApplicationsJapan is expanding the use of genetic testing across preventive healthcare, rare disease diagnosis, and oncology. The market prioritizes reliable laboratory services, efficient diagnostic workflows, and technological innovation that enhances clinical decision-making while supporting an aging population.
South Korea 🇰🇷
Digital Genomics InnovationSouth Korea is combining advanced biotechnology capabilities with digital healthcare infrastructure to strengthen genetic testing services. Companies focus on next-generation sequencing, AI-assisted genomic analysis, and consumer health applications that improve testing accessibility and clinical efficiency.
France 🇫🇷
Personalized Care SupportFrance continues to integrate genetic testing into personalized healthcare through expanding molecular diagnostics and specialized clinical programs. The market emphasizes quality assurance, evidence-based applications, and stronger collaboration between healthcare institutions and genomic research organizations.
Italy 🇮🇹
Specialized Diagnostic NetworksItaly is reinforcing genetic testing through specialized diagnostic centers and increasing adoption of molecular medicine. Healthcare providers prioritize early disease identification, hereditary condition screening, and laboratory modernization to improve diagnostic accuracy across multiple therapeutic areas.
Segment Leadership and Growth Trends
Genetic Testing Market Share (%), by Products & Services, 2026
Go beyond the chart, access full insights & data tables
Request Free Sample ReportProducts & Services Segment Analysis: Kits & Reagents (Largest Segment) vs Software & Services (Fastest-Growing Segment)
In the genetic testing market, the kits & reagents segment held the largest share of 62.5% in 2026. Its leading position is supported by the routine and repeated consumption of reagents across diagnostic laboratories, research institutions, and clinical testing facilities. The expanding use of genetic analysis in disease detection, inherited disorder screening, and precision medicine continues to drive consistent demand for high-quality consumables, making kits and reagents an essential component of testing workflows.
The software & services segment is expected to register the fastest growth as genetic testing generates increasingly complex datasets that require advanced interpretation and efficient data management. Greater reliance on bioinformatics platforms, automated analysis tools, and specialized interpretation services is strengthening demand for software-driven solutions. The growing emphasis on integrating genomic information into clinical decision-making and improving laboratory efficiency further supports the expansion of this segment.
Techniques Segment Analysis: DNA Sequencing (Largest & Fastest-Growing Segment)
Holding the largest share of the genetic testing market, the DNA sequencing segment accounted for 44.1% in 2026 while also emerging as the fastest-growing technique. Its leadership is driven by its ability to provide comprehensive genetic information with high accuracy across a broad range of clinical and research applications. Continuous improvements in sequencing technologies, increasing adoption in personalized medicine, and expanding use in disease diagnosis, inherited disorder analysis, and oncology have strengthened its market position. Growing investments in genomic research and the need for detailed molecular insights are expected to further reinforce the adoption of DNA sequencing across healthcare and life science applications.
Test Type Segment Analysis: Prenatal and Newborn Testing (Largest Segment) vs Carrier Testing (Fastest-Growing Segment)
The prenatal and newborn testing segment dominated with a market share of 42.77% in 2026 due to the increasing emphasis on early identification of genetic abnormalities and inherited disorders. Widespread implementation of newborn screening programs and growing awareness regarding preventive healthcare have encouraged broader adoption of these tests. Healthcare providers are also placing greater importance on early intervention strategies that improve long-term patient outcomes.
Carrier testing is anticipated to witness the fastest growth in the genetic testing market as awareness of inherited disease risks continues to increase among prospective parents and families with a history of genetic disorders. Rising utilization of genetic counseling and proactive reproductive planning has expanded the demand for carrier screening. Advancements in testing technologies and broader accessibility of genetic services are further supporting the rapid adoption of carrier testing.
| Segment | Sub-Segment | Largest Segment | Fastest Growing |
|---|---|---|---|
| Products & Services | Kits & Reagents, Software & Services | Kits & Reagents | Software & Services |
| Techniques | Polymerase Chain Reaction, DNA Sequencing, Cytogenetic Testing, Microarrays, Gene Expression Profiling | DNA Sequencing | DNA Sequencing |
| Test Type | Predictive Testing, Carrier Testing, Prenatal and Newborn Testing, Diagnostic Testing, Pharmacogenomic Testing, Nutrigenomics, Others | Prenatal and Newborn Testing | Carrier Testing |
| End-use | Hospitals & Clinics, Diagnostic Laboratories, Forensic Laboratories, Others | Hospitals & Clinics | Diagnostic Laboratories |
| Application | Cancer Treatment, Tissue Typing for Transplantation, Forensic Identity Testing, Ancestry Testing, Paternity Testing, Others | Cancer Treatment | Cancer Treatment |
Competitive Landscape and Market Positioning
Prominent players in the genetic testing market:
- Illumina, Inc. (United States)
- Thermo Fisher Scientific, Inc. (United States)
- QIAGEN N.V. (Netherlands)
- Quest Diagnostics Incorporated (United States)
- Natera, Inc. (United States)
- Myriad Genetics, Inc. (United States)
- BGI Genomics Co., Ltd. (China)
- 23andMe Holding Co. (United States)
- Siemens Healthineers AG (Germany)
- Abbott Laboratories (United States)
Scientific innovation and expanding clinical adoption continue to redefine competitive dynamics in the Genetic Testing Market, with differentiation increasingly emerging from testing accuracy, interpretation capabilities, and the breadth of diagnostic applications. Market participants are strengthening their positions through improvements in sequencing technologies, bioinformatics platforms, and integrated data analysis that enable more actionable clinical insights across preventive care, disease diagnosis, and personalized medicine. Competition is also extending beyond laboratory performance toward workflow efficiency, regulatory compliance, and the ability to support healthcare providers with scalable testing services. Growing emphasis on data privacy, clinical validation, and standardized reporting further elevates the importance of trusted diagnostic platforms capable of meeting evolving healthcare requirements across multiple care settings.
| Company | Market Share | Company Revenue | Revenue CAGR (%) | Product Portfolio | Geographic Presence | Innovation / R&D Focus | Strategic Developments |
|---|---|---|---|---|---|---|---|
| Illumina Inc. (United States) | |||||||
| Thermo Fisher Scientific Inc. (United States) | |||||||
| QIAGEN N.V. (Netherlands) | |||||||
| Quest Diagnostics Incorporated (United States) | |||||||
| Natera Inc. (United States) | |||||||
| Myriad Genetics Inc. (United States) | |||||||
| BGI Genomics Co. Ltd. (China) | |||||||
| 23andMe Holding Co. (United States) | |||||||
| Siemens Healthineers AG (Germany) | |||||||
| Abbott Laboratories (United States) |
Industry Development/News
| Company Name | Date | Key Development |
|---|---|---|
| Vitalant | Jun-26 | Vitalant expanded its next-generation sequencing infrastructure at its Pittsburgh laboratory, linking it with Phoenix and San Francisco sites into a hub-and-spoke production network. The expansion scales analytical capacity for cell therapy development and bleeding disorder diagnostics. |
| Labcorp | Apr-26 | Labcorp partnered with the Children's Hospital of Philadelphia to accelerate the development and commercialization of pediatric specialty diagnostics, directly expanding hospital access to advanced pediatric genetic testing panels. |
| PrecisionLife | Apr-26 | PrecisionLife partnered with Ovation.io to commercialize direct-to-consumer and laboratory-developed genetic tests. The diagnostic panels predict individual patient efficacy and response variations to GLP-1 therapies, extending precision medicine applications. |
| SumHealth | Sep-25 | SumHealth partnered with Nucleus Genomics to integrate clinical-grade whole-genome DNA testing across commercial hospitals, pharmacies, and regional health systems, expanding the institutional distribution network for comprehensive genomic testing. |
| VieCure | Jul-25 | VieCure partnered with Guardant Health to integrate liquid biopsy and solid tissue genomic testing data into AI-powered oncology workflows, building real-time clinical decision support loops for decentralized community oncology practices. |
| QIAGEN | May-25 | QIAGEN acquired Israeli AI genomics developer Genoox for approximately US$80 million. The transaction integrates Genoox's Franklin platform into QIAGEN's portfolio, expanding its clinical genetic testing footprint with advanced, AI-powered genomic interpretation software capabilities. |
| GeneDx | Apr-25 | GeneDx acquired Fabric Genomics to merge its clinical laboratory infrastructure with Fabric's AI-driven variant prioritization software. The acquisition scales its clinical genetic testing throughput and accelerates turnaround times for rare disease diagnostics. |
| Labcorp | Aug-24 | Labcorp acquired select genetic testing assets and technology infrastructure from Invitae. The transaction directly expands Labcorp's personalized medicine market share, strengthening its commercial oncology and reproductive health diagnostic portfolios. |
| Baylor Genetics | Aug-24 | Baylor Genetics and Baylor College of Medicine co-launched the Medical Genetics Multi-Omics Laboratory. The new facility expands specialized clinical capacity, uniting routine genetic testing workflows with high-throughput multi-omics research. |
| Sysmex Corporation | Feb-24 | Sysmex Corporation and Hitachi High-Tech Corporation entered a strategic development partnership to engineer advanced genetic testing systems using capillary electrophoresis sequencers. The alignment aims to scale manufacturing and enter untapped international markets. |
Customize Your Report
Explore examples of how this report can be tailored to different research needs, including custom segments, additional topics or chapters, and related reports. Click a section of the wheel or its numbered marker to explore the available options.
Genetic Testing Market — Custom Segments
| Segment | Sub-Segment |
|---|---|
| Genetic Variant Type | Single-nucleotide Variants, Copy Number Variants, Structural Variants, Repeat Expansions |
| Sample Type | Blood, Saliva/Buccal Swab, Tissue, Amniotic Fluid, Other Body Fluids |
| Reimbursement Status | Reimbursed, Partially Reimbursed, Self-pay |
Genetic Testing Market — Custom TOC
| Custom Chapter | Custom Details |
|---|---|
| Clinical Adoption Pathways |
|
| Precision Medicine Integration |
|
| Genetic Testing Reimbursement Landscape |
|
Need a different cut of the data?
Request Custom ResearchHow much is the genetic testing market worth?
How is the genetic testing industry projected to perform over the next decade?
How is personalized medicine influencing growth in the genetic testing market?
Why are direct-to-consumer services expanding the genetic testing market?
Which products and services segment held the largest share in the genetic testing market?
Why is carrier testing expected to be the fastest-growing test type in the genetic testing market?
What makes North America the leading region for genetic testing?
What is driving genetic testing adoption in Asia Pacific?
What are the key competitors in the genetic testing landscape?
Our Clients
"The team took the time to understand our specific business needs and delivered a report that was well aligned with our objectives. Their expertise and understanding of the industry were clearly reflected in the quality and relevance of the insights provided."
Siemens Healthcare
"Our experience in acquiring the research report has been excellent. The depth of analysis, and actionable insights provided have been extremely valuable in supporting our ongoing R&D efforts."
GC Biopharma
"The report offered a comprehensive view of the market trends. The in-depth segmentation and analysis of emerging opportunities gave us a better understanding of the market."
Medtronic
Our Research Team & Methodology
Every Fundamental Business Insights report is built by a dedicated vertical research team, validated through a structured primary-and-secondary methodology, and reviewed for accuracy before it reaches you.
Research Team Overview
Prepared by the Healthcare & Medical Devices Research Team
Delivery
Published
Demand
Available
Support
Trust & Compliance
Research Domains
10 coverage areasResearch Intelligence
| Source | Reference |
|---|---|
| World Health Organization (WHO) | www.who.int |
| U.S. Food & Drug Administration (FDA) | www.fda.gov |
| European Medicines Agency (EMA) | www.ema.europa.eu |
| Centers for Disease Control and Prevention (CDC) | www.cdc.gov |
| National Institutes of Health (NIH) | www.nih.gov |
| National Center for Biotechnology Information (NCBI) | www.ncbi.nlm.nih.gov |
| PubMed | pubmed.ncbi.nlm.nih.gov |
| ClinicalTrials.gov | clinicaltrials.gov |
| International Organization for Standardization (ISO) | www.iso.org |
| ASTM International | www.astm.org |
| Advanced Medical Technology Association (AdvaMed) | www.advamed.org |
| Medical Device Innovation Consortium (MDIC) | mdic.org |
| Biotechnology Innovation Organization (BIO) | www.bio.org |
| International Federation of Pharmaceutical Manufacturers & Associations (IFPMA) | www.ifpma.org |
| U.S. Pharmacopeia (USP) | www.usp.org |
| European Directorate for the Quality of Medicines & HealthCare (EDQM) | www.edqm.eu |
| World Organisation for Animal Health (WOAH) | www.woah.org |
| American Hospital Association (AHA) | www.aha.org |
| OECD Health | www.oecd.org/health |
| World Bank Data | data.worldbank.org |
Research Workflow & Quality Assurance
Data Collection
Verified information gathered through primary and secondary research.
Data Triangulation
Cross-validation using multiple independent data sources.
Forecast Modelling
Market estimates developed using historical trends and analytical models.
Analyst Validation
Findings reviewed by domain experts for accuracy and consistency.
Editorial & Quality Review
Final editorial, quality, and compliance checks before publication.
Final Publication
Released after successful completion of the internal review process.
Report Coverage
📊 Market Assessment
- Market Size & Forecast
- Market Segmentation
- Regional Analysis
- Growth Drivers & Challenges
- Market Dynamics
🏢 Competitive Intelligence
- Competitive Landscape
- Company Profiles
- Competitive Benchmarking
- Mergers & Acquisitions
- Market Share Analysis or Key Company Strategies
🔍 Strategic Analysis
- Value Chain Analysis
- Porter's Five Forces
- PESTLE Analysis
- Pricing Trends
- Supply-Demand Analysis
🚀 Future Outlook
- Technology Landscape
- Regulatory Landscape
- Investment & Funding Landscape
- Emerging Opportunities
- Future Market Outlook
Have a question about this report or need a custom scope?
Request Customization